Ignite Creation Date:
2025-12-24 @ 3:23 PM
Ignite Modification Date:
2026-01-02 @ 3:31 AM
Study NCT ID:
NCT01458392
Status:
COMPLETED
Last Update Posted:
2022-10-05
First Post:
2011-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-10
Start Date Type:
None
Primary Completion Date:
2015-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-09
Completion Date Type:
ACTUAL
First Submit Date:
2011-10-20
First Submit QC Date:
None
Study First Post Date:
2011-10-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-04-11
Results First Submit QC Date:
None
Results First Post Date:
2017-06-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-13
Last Update Post Date:
2022-10-05
Last Update Post Date Type:
ACTUAL